{
  "docId": "019de073-9f6d-75d9-b724-0b887fde2468",
  "docSlug": "f957aa564e21bc93d4cc30c084ec8efa",
  "documentTitle": "Aldeyra Therapeutics | Results Presentation Deck | 13 slides",
  "authorId": "aldeyra-therapeutics",
  "authorName": "Aldeyra Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 13,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9f6d-75d9-b724-0b887fde2468/5",
  "deckHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468",
  "deckJsonHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468.json",
  "deckAnchorHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "PVR is a rare disease, with ~4,000 patients per year in the U.S. Left untreated, retinal detachment due to PVR can progress to permanent blindness. There is currently no FDA- or EMA-approved therapy. Repeat surgery, which can lead to vision loss, is currently one of the main courses of action.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f90796c-5d8a-4757-9c4e-7aa5e1efb66e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "ADX-2191 was granted U.S. FDA Orphan Drug Designation and U.S. FDA Fast Track Designation for the prevention of PVR, and EU Orphan Medicinal Product Designation for the treatment of retinal detachment. Tolerability and reattachment success demonstrated in Phase 1b open-label investigator sponsored clinical trial. Published clinical data support the use of methotrexate for the prevention of recurrent retinal detachment due to PVR.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50ffbf9c-659d-425e-8cbe-cb5d7463be63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Aldeyra internal estimates. Data on file. PVR = proliferative vitreoretinopathy. ADX-2191 (methotrexate injection, USP) for intravitreal administration is an investigational drug candidate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85a73d11-be50-4c1e-89c7-d88980333c43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "ADX-2191 Represents a Novel Potential Therapeutic Option For the Prevention of Proliferative Vitreoretinopathy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0a0877d-d37e-4bcf-b515-f6333adf294a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "df29b659-515d-45c8-8ba6-9604d7ed1eba",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the problem of PVR and its limitations",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 6,
      "from": 5,
      "beatId": "54f8e12e-7fd5-45cf-89f7-6e83cf808f85",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the inadequacies of current treatments for PVR",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1d3668f3-e0c4-45a4-bfb2-24984220d898",
      "evidence": "The document implies the cost of inaction by highlighting the limitations of current treatments",
      "position": 0,
      "objective": "What is the cost of not treating PVR effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}